PREPARE – Phase-III-Studie zur Erstlinientherapie des unbehandelten fortgeschrittenen oder metastasierten NierenzellkarzinomsProaktive Begleitung der Therapie mit Sunitinib, Pembrolizumab plus Axitinib oder Avelumab plus AxitinibPREPARE—phase III trial of first-line therapy of treatment-naïve advanced or metastatic renal cell carcinomaProactive coaching during treatment with sunitinib, pembrolizumab, and axitinib or avelumab with axitinib

被引：0
|
作者：
H. Rexer
V. Grünwald
C. Doehn
机构：
[1] AUO-Geschäftsstelle,
[2] Universitätsklinikum Essen,undefined
[3] Organgruppe Nierenzellkarzinom der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft,undefined
来源：
Forum | 2021年 / 36卷 / 3期
关键词：
D O I：
10.1007/s12312-021-00920-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：253 / 255
页数：2
相关论文
共 24 条
  • [1] KEYNOTE-426Axitinib plus Pembrolizumab vs. Sunitinib in der Erstlinientherapie des metastasierten NierenzellkarzinomsKEYNOTE-426Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    J. Bedke
    V. Stühler
    [J]. Der Urologe, 2020, 59 (7): : 841 - 842
  • [2] Eine Phase-III-Studie zur pro-aktiven Therapiebegleitung unter Behandlung mit Sunitinib oder Pembrolizumab in Kombination mit Axitinib bzw. Avelumab in Kombination mit Axitinib eines fortgeschrittenen oder metastasierten Nierenzellkarzinoms (PREPARE) – AUO-Nr. AN 49/18
    不详
    [J]. Der Urologe, 2020, 59 (9): : 1157 - 1159
  • [3] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [4] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] First-line Therapy Study of untreated advanced or metastatic Renal Cell Cancer A Phase III Trial of pro-active Therapy Monitoring during the Treatment with Sunitinib or Pembrolizumab in combination with Axitinib or Avelumab in Combination with Axitinib for Patients with advanced or metastatic Renal Cell Cancer (PREPARE) - AUO Study AN 49/18
    Rexer, Heidrun
    Gruenwald, Viktor
    Doehn, Christian
    [J]. AKTUELLE UROLOGIE, 2022, 53 (03) : 222 - 225
  • [6] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Subsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
    Gafanov, R.
    Powles, T. B.
    Bedke, J.
    Stus, V.
    Waddell, T. S.
    Nosov, D.
    Pouliot, F.
    Soulieres, D.
    Melichar, B.
    Azevedo, S.
    McDermott, R. S.
    Vynnychenko, I. O.
    Borchiellini, D.
    Markus, M.
    Bondarenko, I.
    Lin, J.
    Burgents, J.
    Molife, L. R.
    Plimack, E. R.
    Rini, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S694 - S694
  • [8] PREPAREPhase-III-Studie zur proaktiven Therapiebegleitung (Coaching) in Bezug auf die Patienteneinschätzung der Lebensqualität unter Behandlung eines fortgeschrittenen oder metastasierten Nierenzellkarzinoms mit Checkpoint-Inhibitoren plus Axitinib oder Sunitinib-MonotherapiePREPAREA phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + checkpoint inhibitor (CPI) in first line therapy
    V. Grünwald
    P. Ivanyi
    L. Jakobasch
    M.-O. Zahn
    B. Eberhardt
    M. Detzner
    [J]. Forum, 2020, 35 (2) : 152 - 154
  • [9] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
    Yan, X. Q.
    Yey, M. J.
    Zou, Q.
    Chen, P.
    He, Z. S.
    Wu, B.
    He, D. L.
    He, C. H.
    Xue, X. Y.
    Ji, Z. G.
    Chen, H.
    Zhang, S.
    Liu, Y. P.
    Zhang, X. D.
    Fu, C.
    Xu, D. F.
    Qiu, M. X.
    Lv, J. J.
    Huang, J.
    Ren, X. B.
    Cheng, Y.
    Qin, W. J.
    Zhang, X.
    Zhou, F. J.
    Ma, L. L.
    Guo, J. M.
    Ding, D. G.
    Wei, S. Z.
    He, Y.
    Guo, H. Q.
    Shi, B. K.
    Liu, L.
    Liu, F.
    Hu, Z. Q.
    Jin, X. M.
    Yang, L.
    Zhu, S. X.
    Liu, J. H.
    Huang, Y. H.
    Xu, T.
    Liu, B.
    Sun, T.
    Wang, Z. J.
    Jiang, H. W.
    Yu, D. X.
    Zhou, A. P.
    Jiang, J.
    Luan, G. D.
    Jin, C. L.
    Xu, J.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (02) : 190 - 199
  • [10] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem Airatovich
    Hawkins, Robert E.
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
123